Clinical Trial Update: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study of ixekizumab in children with juvenile idiopathic arthritis subtypes Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis has posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enthesitis-related Arthritis
• Juvenile Psoriatic Arthritis

Drugs mentioned

• Ixekizumab (ixekizumab)
• TALTZ (IXEKIZUMAB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-05